Comparison of an Artificial Pancreas Versus Threshold Low Glucose Suspend in Type 1 Diabetic Children (SHAN)
Assessment of the Efficacy on the Reduction of Nocturnal Hypoglycemia in Children With Type 1 Diabetes of a Closed-loop Insulin Therapy (Artificial Pancreas) Compared to Insulin Pump Therapy Combined With Continuous Glucose Monitoring With Threshold Low Glucose Suspend of Infusion in Home-like Conditions
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Detaljeret beskrivelse
Undersøgelsestype
Undersøgelsestype
Tilmelding (Faktiske)
Tilmelding
Fase
Fase
- Fase 2
Kontakter og lokationer
Studiesteder
-
-
-
Angers, Frankrig, 49000
- CHU d'Angers
-
Montpellier, Frankrig, 34985
- CHU Montpellier - Hôpital Lapeyronie
-
Paris, Frankrig, 75019
- AP-HP, Hôpital Robert Debré
-
Tours, Frankrig, 37000
- CHU de Tours, Hôpital Clocheville
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Age from 7 to 12
- Puberty status at Prader 1
- Diabetes diagnosed according to WHO criteria since more than 1 year
- Fasting plasma C-peptide level <0.2 ng/ml for a fasting blood glucose level < 180 mg/dl
- At least one positiveness for plasma antibodies against pancreatic islets: IAA, IA2, GAD, ICA or ZnT8, since diagnosis of diabetes
- Treatment of diabetes by insulin pump since more than 6 months
- HbA1c level below 8.5%
- Trained in carbohydrate counting
- Lack of any associated disease or therapy (except insulin) affecting glucose metabolism
- Willingness to follow all study procedures
- Informed consent signed by patient and parent or legally responsible party
- Patient must be affiliated or beneficiary of a social medical insurance
Exclusion Criteria:
- Unwillingness of one parent or the legally responsible party to be present during all study procedures
- Expected use of acetaminophen-containing drugs
- Any disease or therapy (except insulin) affecting glucose metabolism during previous month
- Impaired cognitive or psychological abilities which may result in defective adherence to study procedures
- Active enrollment in another clinical trial or participation in a study within 30 days or participation in previous studies resulting in a cumulated annual income which would exceed 4500 €
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Crossover opgave
- Maskning: Ingen (Åben etiket)
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Eksperimentel: Control-to-Range algorithm and Threshold Low Glucose Suspend
On this arm, patients will realize two investigational sessions:
|
The insuline used is usual patient insuline.
There is no specific insulin for this protocol
The insuline used is usual patient insuline.
There is no specific insulin for this protocol
|
|
Eksperimentel: Threshold Low Glucose Suspend and Control-to-Range algorithm
On this arm, patients will realize two investigational sessions:
|
The insuline used is usual patient insuline.
There is no specific insulin for this protocol
The insuline used is usual patient insuline.
There is no specific insulin for this protocol
|
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Time spent with blood glucose <70 mg/dl
Tidsramme: from 22:00 to 08:00, over two consecutive nights
|
from 22:00 to 08:00, over two consecutive nights
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Percent time spent with blood glucose <70mg/dl
Tidsramme: over two consecutive days (48h)
|
over two consecutive days (48h)
|
|
Percent time spent with blood glucose level in 70-180 mg/dl range
Tidsramme: from 22:00 to 08:00 over two consecutive nights
|
from 22:00 to 08:00 over two consecutive nights
|
|
Percent time spent with blood glucose level in 80-150 mg/dl range
Tidsramme: from 22:00 to 08:00 over two consecutive nights
|
from 22:00 to 08:00 over two consecutive nights
|
|
Percent time spent with blood glucose level in 70-180 mg/dl range
Tidsramme: over two consecutive days (48h)
|
over two consecutive days (48h)
|
|
Mean blood glucose level
Tidsramme: from 22:00 to 08:00, over two consecutive nights
|
from 22:00 to 08:00, over two consecutive nights
|
|
Mean blood glucose level
Tidsramme: over two consecutive days (48h)
|
over two consecutive days (48h)
|
|
Number of needed interventions by the patients, the parents, and by the investigational team, to treat hypoglycemia
Tidsramme: during 65 hours of each investigational session
|
during 65 hours of each investigational session
|
|
Number of needed interventions by the patients, the parents, and by the investigational team, to fix issues related to the functioning of the insulin delivery system
Tidsramme: during 65 hours of each investigational session
|
during 65 hours of each investigational session
|
|
Score of the Artificial Pancreas Acceptance Questionnaire
Tidsramme: at time of inclusion (at Visit 2) and 5 to 6 weeks after inclusion (i.e at Visit 4)
|
at time of inclusion (at Visit 2) and 5 to 6 weeks after inclusion (i.e at Visit 4)
|
|
Score of the Hypo Fear Survey
Tidsramme: at time of inclusion (at Visit 2) and 5 to 6 weeks after inclusion (i.e at Visit 4)
|
at time of inclusion (at Visit 2) and 5 to 6 weeks after inclusion (i.e at Visit 4)
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Publikationer og nyttige links
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Studiestart
Primær færdiggørelse (Faktiske)
Primær færdiggørelse
Studieafslutning (Faktiske)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
- Glukosemetabolismeforstyrrelser
- Metaboliske sygdomme
- Sygdomme i immunsystemet
- Autoimmune sygdomme
- Sygdomme i det endokrine system
- Diabetes mellitus
- Diabetes mellitus, type 1
- Hypoglykæmiske midler
- Lægemidlers fysiologiske virkninger
- Insulin
- Insulin, Globin Zink
- Insulin Aspart
- Insulin, langtidsvirkende
- Insulin degludec, insulin aspart lægemiddelkombination
- Insulin Lispro
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- 9525 (Anden identifikator: CTEP)
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .